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Abstract. – OBJECTIVE: Endometriosis is a 
debilitating disease characterized by chronic 
inflammation. The transporter multidrug resis-
tance-associated protein 4 (MRP4/ABCC4) is ex-
pressed in human endometrial tissue; it is over-
expressed in ectopic endometrial tissue, and is 
modulated by the anti-inflammatory lipid Lipox-
in A4 (LXA4). Recently, it was demonstrated that 
aspirin induces platelet MRP4 over-expression, 
through genomic modulation in megakaryocytes. 
Since patients with endometriosis frequent-
ly use aspirin or other non-aspirin Non-Steroi-
dal Anti-Inflammatory Drugs (NSAIDs), the aim 
of this study was to verify whether aspirin and 
other NSAIDs enhance MRP4 expression in 12Z 
human endometriotic epithelial cells and wheth-
er this was peroxisome proliferator-activated re-
ceptor alpha (PPARa) dependent.
MATERIALS AND METHODS: MRP4 and PPA-
Ra expression was analyzed by Q-RT-PCR us-
ing TaqMan® Master Mix and TaqMan® Assay 
Reagents (Life Technologies, Monza, Italy) and 
Western blot. 
RESULTS: In 12Z cells, aspirin and other 
NSAIDs enhanced MRP4 mRNA and protein ex-
pression; these treatments also induced PPARa 
expression. Aspirin and diclofenac-induced in-
creases in MRP4 expression were not observed 
in cells where PPARa was knocked down using 
siRNA. NSAIDs-induced MRP4 expression was 
correlated with augmented PGE2 secretion, in-
dicating functional relevance.
CONCLUSIONS: MRP4 expression was in-
creased in cells treated with NSAIDs and the nu-
clear receptor PPARa is involved. Elevated PGE2 
levels in cell supernatants correlate with its in-
creased transport by MRP4 after NSAID treat-
ment. More importantly, we provide evidence 
that in endometriotic epithelial cells aspirin and 
non-aspirin NSAIDs treatments alter gene ex-
pression.
Key Words: 
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Introduction
Endometriosis is a debilitating disease with 
features of chronic inflammation that affects ap-
proximately 10% of women in reproductive age. It 
is defined as the presence of functional endome-
trial glands and stroma outside the uterine cavity1. 
As one of the most common benign gynecological 
conditions, endometriosis is a debilitating disease 
with detrimental effects on social, occupational 
and psychological functioning2. Despite its pre-
valence, this disease remains poorly understood 
and current studies have proved that there is no 
relationship between the extent of the disease and 
its symptomatology1. The most frequent symptom 
is a chronic pelvic pain, which may include: dy-
smenorrhea (painful periods), periovulatory pain, 
dyspareunia (pain during or after sexual inter-
course), dysuria, dyschezia, and leg pain. For this 
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reason, patients with endometriosis frequently use 
either non-aspirin Non-Steroidal Anti-Inflamma-
tory Drugs (NSAIDs) or aspirin. Endometriosis is 
divided by the classification system of the Ame-
rican Fertility Society into four stages of severity 
from stage I, that is represented by minimal dise-
ase, to stage IV, which means severe disease. Sta-
ging does not correspond with degree or severity 
of symptoms but assesses the extension of disease 
visible by laparoscopy. In addition, an elevated le-
vel of CA125 (epithelial ovarian cancer associated 
antigen) in patients with endometriosis is associa-
ted with the progression of the disease3. Women’s 
quality of life, including their careers, everyday 
activities, sexual and non-sexual relationships 
and fertility may be really affected by endome-
triosis. The United Kingdom – Endometriosis UK 
(www.endometriosis-uk.org/), which represents a 
patient support organization, confirmed that the 
65% of women with endometriosis had negatively 
influenced their employment, the 10% of women 
reduced the hours of work, and 30% of them lost 
the job, which brought them to perceive a fee-
ling of distress and low self-esteem4. Moreover, 
infertility has been identified as one of the most 
relevant complications related to endometriosis, 
which has been observed in 15-25% of patients. 
In 2018, has been demonstrated that the levels of 
inflammatory cytokines (IL-6, IL-10, IL-13, and 
TNF) are particularly increased in peritoneal flu-
id of patients affected by endometriosis compli-
cated with infertility. Therefore, the high level of 
those cytokines may determinate embryo toxicity 
and could affect sperm motility, fertilization, and 
implantation leading to an elevated rate of infer-
tility among patients affected by endometriosis5,6. 
Endometriosis can be suspected in reproductive 
age women with clinical symptoms. Transvaginal 
ultrasonography can reliably detect endometrio-
mas but failure to reveal cystic structures does 
not exclude the diagnosis of endometriosis. Ma-
gnetic resonance imaging (MRI) is increasingly 
used to identify subperitoneal deposits, although 
retroversion, endometrioma, and bowel structu-
res may mask small nodules7. Risk factors gene-
rally relate to menstruation: early menarche, late 
menopause, nulliparity and first pregnancy late 
in life increase the risk whereas the use of oral 
contraceptives is associated with a reduced risk 
of developing the disease. While the etiology of 
endometriosis still remains unclear, the most wi-
dely accepted hypothesis first advanced by Samp-
son8 is that viable endometrial tissue fragments 
are refluxed through the fallopian tubes into the 
pelvic cavity during retrograde menstruation, 
and after being migrated adhere and invade other 
tissues. Different studies9-11 indicate that growth 
factors, cytokines, and prostaglandins promote 
the establishment and maintenance of endome-
triosis. In endometriosis patients, concentrations 
of prostaglandin E2 (PGE2) in the peritoneal fluid 
are higher compared to that of endometriosis-free 
women9; PGE2 plays a pivotal role in endometrio-
sis-associated inflammation and pain12,13. COX-2 
protein is abundantly expressed in ectopic en-
dometrium and in the eutopic endometrium of 
women with endometriosis. Banu et al14, showed 
that inhibition of COX-2 and of PGE2 receptors 
PTGER2 and PTGER4 decrease survival and 
invasion of human endometriotic epithelial and 
stromal cells through multiple mechanisms. Their 
results support that COX-2/PGE2 promotes the 
pathophysiology and pathogenesis of endome-
triosis in humans. The inhibition of PTGER2 and 
PTGER4 in vitro, inhibits adhesion of human en-
dometriotic epithelial cells 12Z and stromal cells 
22B to collagen I, vitronectin, fibronectin, colla-
gen IV, and laminin in a substrate- and epithe-
lial-stromal cell-specific manner of the peritoneal 
extracellular matrix (ECM)15. Together, these re-
sults suggest the importance of the PTGER2 and 
PTGER4 associated signaling pathways in the pa-
thogenesis of endometriosis.
Nonsteroidal anti-inflammatory drugs 
(NSAIDs) are the most frequently used first-line 
drugs for pain in women affected by endome-
triosis. Nevertheless, there is no sufficient evi-
dence that showed whether or not they are really 
effective in relieving endometriosis-associated 
pain. Moreover, it has not been demonstrated if 
there is a NSAID more effective than another4. 
Currently, has been affirmed that the expression 
of COX-2 in ectopic endometrial cells is higher 
than in eutopic endometrium. Nonsteroidal an-
ti-inflammatory drugs inhibit the function of 
the enzyme COX-1 and COX-2, preventing the 
production of PGs, which are implicated in the 
genesis of endometriosis-associated pain. Fur-
thermore, have been registered several side ef-
fects related with NSAIDs including nausea, 
diarrhoea, headache, dryness of the mouth16. 
In 2016 the Cochrane Gynecology and Fertili-
ty Group Specialized Register of Controlled 
Trials published a comparison performed from 
January 2008 to October 2016, by using NSAIDs 
(naproxen) vs. placebo in women with endome-
triosis-related pain. Data revealed no evidence of 
a positive effect on pain relief (odds ratio (OR) 
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3.27, 95% confidence interval (CI) 0.61 to 17.69; 
one trial, 24 women; very low-quality evidence). 
In addition, the work did not demonstrate impro-
vements concerning the quality of life, effects 
on daily activities, absence from work or school 
in patients treated with NSAIDs17. Clinical expe-
riences of our center evaluated the impact of 
NSAIDs, which are used as pain therapy in en-
dometriosis. It showed that 39 (12.8%) out of 305 
patients, did not require any therapy, 84 (27.5%) 
patients did not report if they needed drugs, 18 
patients (5.9%) stated they needed treatment but 
did not specify which therapy. About the remai-
ning patients: 111 (36.4%) take only NSAIDs, 41 
(13.4%) take NSAIDs in combination with other 
drugs, and 12 (3.9%) use drugs different from 
NSAIDs. In our opinion, these data are very im-
portant because, if we sum up all the patients 
who use NSAIDs, alone and in combination, the 
total of the patients who take NSAIDs, increa-
ses to 152 (49.8%). The transporter multidrug 
resistance-associated protein 4 (MRP4) is also 
expressed in human endometrial tissue; it is ove-
rexpressed in the ectopic endometrial tissue, and 
is modulated by the anti-inflammatory lipid li-
poxin A4 (LXA4)
11. Increased MRP4 expression 
in the ectopic endometrium of women suffering 
from endometriosis was confirmed by a subse-
quent study18. MRP4, an ATP binding cassette 
(ABCC4) and unidirectional transporter of en-
dogenous molecules including several PGs, plays 
a key role in cellular communication and signa-
ling. Elevated MRP4 expression may result in 
increased extracellular PGE2, which binds its re-
ceptors and activates various signaling pathways 
in endometriosis. MRP4, as well as PGE2 itself, 
is implicated in proliferative conditions and 
could, therefore, serves as a potential biomarker 
for disease severity, as well as a possible drug 
target for endometriosis therapy13. We demon-
strated that aspirin causes MRP4 overexpression 
in human platelets, through an activation of the 
nuclear receptor PPARa in megakaryocytes19. 
Recently we reported that non-aspirin Non-Ste-
roidal Anti-Inflammatory Drugs (NSAIDs) can 
induce MRP4 overexpression in human pla-
telets. Patients with endometriosis frequently 
suffer from dysmenorrhea, which negatively 
affects daily activities, and for this reason, they 
frequently take aspirin or non-aspirin NSAIDs20. 
We can assume that MRP4 can be modulated by 
the action of aspirin and non-aspirin NSAIDs 
even in the endometrium, leading to enhance-
ment of PGE2 secretion. In this study the role 
of aspirin and non-steroidal anti-inflammatory 
drugs (NSAIDs) in regulating MRP4 expression 
in human endometriotic epithelial cells (12Z), 
the involvement of nuclear receptor PPARa and 
PGE2 secretion were investigated.
Materials and Methods
Cell Culture
The simian virus 40 T-antigen-transformed 
human ectopic endometriotic epithelial cell line, 
12Z (kindly provided by Dr. M. Beste, Massachu-
setts Institute of Technology), was maintained in 
Dulbecco’s Modified Eagle Medium (DMEM)/
Ham’s F12 medium supplemented with 10% he-
at-inactivated fetal bovine serum (FBS), 20 mM 
L-glutamine, 100 units/ml of penicillin G sodium, 
and 100 μg/ml streptomycin sulphate in a humi-
dified atmosphere containing 5% CO2 at 37°C
21. 
For stimulation experiments, cells (250,000/well) 
were seeded in 12-well plates; the following day, 
stimulation with various factors was carried out 
in media for 48 h. Cells were treated with either 
aspirin (25 μM, 50 μM, and 100 μM), or diclofe-
nac (25 μM, 50 μM, and 100 μM), or nimesulide 
(25 μM, 50 μM, and 100 μM), or acetaminophen 
(50 μM), or ketoprofen (50 μM), or ibuprofen (50 
μM), or naproxen (50 μM). In a mock culture, an 
equivalent amount of DMSO, the vehicle, was 
added. After treatment, cells were processed for 
RNA and protein extraction. For PGE2 analysis 
and measurement of prostaglandin H synthase 
activity, 12Z cells (250,000/well) were seeded 
in 12-well plates; the following day, stimulation 
with various factors was carried out in media for 
48 h (50 uM aspirin or diclofenac or nimesulide). 
After 48 hours of treatment, cells were washed 
and maintained in medium without any drugs for 
24 hours, after which supernatants were collected 
for PGE2 and cells collected for the measurement 
of prostaglandin H synthase activity and MRP4 
expression.
Protein Extraction and Western Blot
To analyze MRP4 protein, cells were washed 
twice with cold phosphate-buffered saline (PBS), 
collected and centrifuged at 400 g for 10 min. 
Cell pellets were then resuspended in lysis buffer 
(RIPA buffer: 10 mM Tris-HCl pH 7.6, 160 mM 
NaCl, 1 mM EGTA, 1% Deoxycholic acid, 1% 
Triton, 0.1% SDS), incubated on ice for 30 min 
and centrifuged at 12,000 g for 30 min, the super-
natant was then collected. Protein extracts (30 μg) 
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were incubated at 37°C for 30 min and separated 
on 4-12% sodium dodecyl sulphate-polyacryla-
mide gel electrophoresis (SDS-PAGE) gel, tran-
sferred onto polyvinylidene difluoride (PVDF) 
membrane (GE Healthcare, Milano, Italy), and 
probed with rat anti-MRP4 (Alexis, Plymouth 
Meeting, PA, USA) and mouse anti-actin (San-
ta Cruz Biotechnology, Santa Cruz, CA, USA) 
monoclonal antibodies. Immunoreactive bands 
were visualized by enhanced chemiluminescence 
(PerkinElmer, Waltham, MA, USA). The densito-
metric analysis was performed with the National 
Institutes of Health ImageJ analyzer program.
RNA Preparation and Real-Time 
Quantitative PCR Analysis
Total RNA from human cell lines was extracted 
using TRIzol reagent (Invitrogen, Carlsbad, CA, 
USA). For mRNA detection 1 μg of total RNA was 
transcribed using the GeneAmp Gold RNA PCR 
Reagent Kit pAW109 (Life Technologies, Mon-
za, Italy) according to the manufacturer’s proto-
col. Gene expression analysis was carried out by 
means of Q-RT-PCR using TaqMan® Master Mix 
and TaqMan® Assay Reagents (Life Technologies, 
Monza, Italy). The amplification program, moni-
tored using ABI Prism 7900 Sequencer Detector 
(Life Technologies, Monza, Italy), was as follows: 
50°C for 2 min, 95°C for 10 min, 95°C for 15 sec, 
and 60°C for 1 min, the latter two temperatures 
were repeated for 40 cycles. All amplification re-
actions were performed in duplicate using 25 ng 
of cDNA. Changes in MRP4, PPARa and ACTIN 
mRNA amounts were quantified using the ΔΔCt 
method for relative quantification of gene expres-
sion using SDS software version 2.3 (Life Tech-
nologies, Monza, Italy).
RNA Interference
Double strand interfering RNA (siRNA) tar-
geting human PPARa and control non-specific 
siRNA (Santa Cruz Biotechnology, Santa Cruz, 
CA, USA) were transfected using Lipofectamine 
RNAi MAX Reagent (Life Technologies, Monza, 
Italy). 24 hours after siRNA administration, cells 
were treated with aspirin (50 µM) or diclofenac 
(50 µM) (Sigma-Aldrich Chemicals Company, St. 
Louis, MO, USA). 48 hours after treatment, cells 
were processed for RNA and protein analysis.
PGE2 Quantification
For PGE2 analysis, 12Z cells (250,000/well) 
were seeded in 12-well plates and treated as de-
scribed above. Supernatants were then collected 
and PGE2 levels were quantified using a mono-
clonal PGE2 EIA kit (Cayman Chemical Co., Ann 
Arbor, MI, USA) according to the manufacturer’s 
instructions. PGE2 levels (pg/10
5 cells) are repor-
ted as ratio between treated and untreated cells 
(relative levels).
Measurement of Prostaglandin 
H Synthase Activity
Prostaglandin H synthase activity was per-
formed as previously described 22. Briefly, cells 
were washed with PBS and pre-loaded with 2 µM 
5-(and-6)-carboxyl-2’,7’-dichlorodihydrofluore-
scein (CDCF) (Molecular Probes Inc., Eugene, 
OR, USA), serving as a reducing substrate for the 
peroxidase activities of COX-1. Platelet COX acti-
vity was measured as arachidonic acid induced 
(8 µM) fluorescence enhancement in a Victor-3 
spectrofluorimeter (PerkinElmer, Waltham, MA, 
USA), thermostatically regulated (37°C). 5 µM 
Nicotinamide adenine dinucleotide phosphate 
oxidase inhibitor (diphenyliodonium) was added 
to avoid reactive oxygen species production-me-
diated interference. The results are reported as 
the rise in CDCF fluorescence (Arbitrary Units) 
recorded for 5 min.
Statistical Analysis
Data are presented as mean ±SD. The level of 
significance was determined employing unpaired, 
2-tailed Student’s t-test (KaleidaGraph software 
3.6). Results were considered statistically signi-
ficant if a p-value of less than 0.05 was reached.
Results
MRP4 Expression in NSAID Treated 12Z Cells
The effect of aspirin and other NSAIDs on 
MRP4 over-expression has recently been demon-
strated in a human megacaryoblastic cell line 
(DAMI)19,20. In order to examine whether these 
drugs also induced MRP4 expression in endo-
metriotic cells, we treated 12Z cells with aspirin, 
diclofenac, nimesulide, acetaminophen, ketopro-
fen, ibuprofen, and naproxen for 48 hours. Among 
the NSAIDs used, aspirin (1.6 fold increase), di-
clofenac (1.6 fold increase), acetaminophen (1.6 
fold increase), ketoprofen (1.9 fold increase) and 
nimesulide (2.3 fold increase) induced a signifi-
cant increase in MRP4 mRNA expression in 12Z 
cells compared to the control culture (all p<0.05) 
(Figure 1). In contrast, in 12Z cells treated with 
naproxen and ibuprofen, no increase in MRP4 
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expression was observed (Figure 1). In the same 
experimental conditions, Western Blot analysis 
revealed augmented MRP4 protein expression in 
12Z cells treated with aspirin, diclofenac, aceta-
minophen, ketoprofen, and nimesulide (50 μM for 
48 h) (Figure 2A). Densitometric analysis showed 
a statistically significant increase in MRP4 pro-
tein expression in 12Z cells treated with aspirin 
(1.6 fold increase), diclofenac, acetaminophen, 
ketoprofen, and nimesulide (1.4 fold increase) in 
comparison with untreated cells (p<0.05) (Figu-
re 2B). We recently demonstrated that the nuclear 
receptor PPARa is involved in the aspirin-indu-
ced MRP4 overexpression in megakaryocytes19. 
To explore whether PPARa was responsible for 
the MRP4 expression increases in NSAID treated 
12Z cells, we analyzed PPARα mRNA expression. 
The results obtained show that treatment with all 
NSAIDs used, resulted in a significant increase in 
PPARα mRNA expression compared with untre-
ated cells (1.6 fold increase) (p<0.05), except for 
naproxen and ibuprofen (Figure 3). Figure 4 (A-F) 
shows a correlation between MRP4 and PPARα 
expression and scalar increasing doses of aspirin, 
diclofenac, and nimesulide (from 25 μM to 100 
μM). MRP4 expression was strongly induced in a 
dose-dependent manner after aspirin (Figure 4A), 
diclofenac (Figure 4B) and nimesulide (Figure 
4C) treatment. Indeed, the highest MRP4 mRNA 
increase is evident after treatment with 100 μM of 
these drugs. These increases are also evident for 
PPARα expression levels after a different dose of 
drug treatment, for aspirin (Figure 4D), diclofe-
nac (Figure 4E) and nimesulide (Figure 4F).
PPARα siRNA Inhibits MRP4 Expression 
Induced by NSAIDs 
To confirm the involvement of PPARa in 
MRP4 up-regulation, 12Z cells were transfected 
with PPARa specific siRNA (PPAR-si); cells 
transfected with PPAR-si didn’t exhibit any signi-
ficant increase in PPARa mRNA expression after 
aspirin treatment; while cells transfected with 
control, non specific siRNA (CTR-si), exhibited 
the same aspirin-induced expression changes as 
untransfected cells (1.8 fold increase; p<0.05) 
(Figure 5A). Similarly, no change in aspirin de-
pendent MRP4 expression was observed in cells 
treated with PPAR-si, unlike those found in CTR-
si transfected cells (1.8 fold increase; p<0.05) (Fi-
Figure 1. Aspirin and NSAIDs induce MRP4 mRNA 
expression in 12Z cells. Q-RT-PCR analysis of endogenous 
MRP4 expression in 12Z cells treated with aspirin, diclo-
fenac, acetaminophen, ketoprofen, nimesulide, naproxen 
and ibuprofen (50 μM for 48 h) compared to vehicle con-
trol (Ctr). Data were normalized with ACTB expression and 
reported as mean ±SD of 3 experiments (*p<0.05; NS: not 
significant; t-test).
Figure 2. Aspirin and NSAIDs increase MRP4 protein 
expression in 12Z cells. (A) A representative Western Blot, 
of 3 performed, of MRP4 expression in 12Z cells treated 
with aspirin, diclofenac, acetaminophen, ketoprofen and 
nimesulide (50 μM for 48 h). (B) Densitometric analysis 
reported as the ratio between treated (aspirin, diclofenac, 
acetaminophen, ketoprofen and nimesulide) and untreated 
cells (Ctr). Data are reported as mean ±SD; statistical si-
gnificance was evaluated using Student’s t-test for unpaired 
samples (*p<0.05).
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gure 5B). To confirm that aspirin induces PPARa 
activation through COX1 inhibition, we studied 
diclofenac-induced PPARa-MRP4 up-regulation 
in siRNA transfected cells. Among all non-aspi-
rin NSAIDs previously reported, diclofenac was 
chosen because it induces a similar increase in 
MRP4 expression to that caused by aspirin. Also 
in this case, no significant difference in PPARα 
mRNA expression in cells transfected with PPAR-
si was observed after diclofenac treatment; while 
cells transfected with control, non specific siRNA 
(CTR-si), exhibited the same diclofenac induced 
expression changes as untransfected cells (2.1 
fold increase; p<0.05) (Figure 5A). Similarly, no 
increase in diclofenac dependent MRP4 expres-
sion was detected in cells treated with PPAR-si, 
unlike those found in CTR-si transfected cells (1.8 
fold increase; p<0.05) (Figure 5B). 
NSAID-Induced MRP4 Expression 
Correlates with Increased PGE2 
Secretion by Endometriotic Epithelial 
Cells
MRP4 may be relevant to endometriosis patho-
physiology as increases extracellular secretion 
of PGE2, which binds its receptors and activates 
various signaling pathways13. PGE2 is long known 
to promote inflammation and pain, and it is con-
sidered to be a pivotal mediator for endometriosis 
development and progression13,14. To determine 
whether NSAIDs induced MRP4 up-regulation 
was functionally relevant in endometriotic cells, 
we measured PGE2 in 12Z cell supernatants after 
24 hours suspension of NSAID treatment (50 μM 
for 48 hours). In order to avoid a possible role of 
NSAID cell treatment in the inhibition of PGE2 
formation, PGE2 levels were evaluated 48 hours 
after the last drug treatment, when the MRP4 
expression is still high and prostaglandin H syn-
thase activity is not affected by drug treatment. 
In fact, in treated cells, MRP4 protein expression 
after 48h was still up-regulated and prostaglandin 
H synthase activity was equal to untreated cells 
(data not shown). As shown in Figure 6, PGE2 lev-
els were significantly elevated after treatment with 
aspirin (1.75 fold increase; p<0.01), diclofenac 
(1.20 fold increase; p<0.05) and nimesulide (1.48 
fold increase; p<0.05) compared to control cells 
(3.7± 1.1 pg/105 cells). These data demonstrate 
that NSAID-induced MRP4 enhancement is cor-
related with enhanced PGE2 secretion. 
Discussion
Patients with endometriosis frequently suffer 
from dysmenorrhea, periovulatory pain, dyspareu-
nia, dyspareunia, chronic pelvic pain, dysuria, dy-
schezia, and leg pain. Schlincke in 1946 illustrated 
for the first time a case of endometriosis-induced 
sciatica, which is considered one of the most com-
mon causes in women affected by sciatica. Leg 
pain has been reported by 4% of women with chro-
nic pelvic pain and it is described that 40% of wo-
men affected by endometriosis have leg pain23,24. 
Furthermore, leg pain is a common and disabling 
symptom related to endometriosis but it is still 
difficult to determine its cause. We recognize two 
main causes of endometriosis related leg pain: 
referred pain and neuropathic pain. Our studies 
proved that leg pain in patients with endometrio-
sis may be caused to nerve injury or it may be a 
referred dysmenorrheal pain. The most commonly 
implicated nerve is the sciatic nerve. In 2013, we 
showed in a case-control study that pain generally 
affects the left leg (70% of patients versus 30% of 
patients in which pain interests the right leg) and it 
has a usual distribution in the crural and the lateral 
region of the thigh. In our study, 30% of women 
Figure 3. Aspirin and NSAIDs also augment endoge-
nous PPARα mRNA expression in 12Z cells. Q-RT-PCR 
analysis of endogenous PPAR-alpha expression in 12Z cells 
treated with aspirin, diclofenac, acetaminophen, ketopro-
fen, nimesulide, naproxen and ibuprofen (50 μM for 48 h) 
compared to control culture (Ctr). Data were normalized 
with ACTB expression and reported as mean ±SD of 3 expe-
riments (*p<0.05; NS: not significant; t-test).
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demonstrated a decreased nociceptive and tactile 
sensibility in the crural region of the thigh and a 
positive Wasserman test, suggesting the hypothesis 
of femoral nerve involvement25. Therefore, endo-
metriosis may be considered a debilitating disease 
characterized by chronic pain. This is the reason 
why patients with endometriosis often use non-a-
spirin Non-Steroidal Anti-Inflammatory Drugs 
(NSAIDs). Furthermore, it has been confirmed that 
Thrombin-activated fibrinolytic inhibitor (TAFI) is 
largely expressed in endometriosis and causes epi-
thelial mesenchymal transition (EMT), which in-
creases the cell proliferation and invasion26. MRP4 
is expressed in the human endometrium and its 
expression can be up-regulated in ectopic endome-
trium of women suffering from endometriosis and 
modulated by the anti-inflammatory lipid Lipoxin 
A4 (LXA4)
13,18. This transporter likely plays an im-
portant role in the pathogenesis of endometriosis, 
because it facilitates PGE2 secretion. We recently 
demonstrated that aspirin and non-aspirin NSAIDs 
drugs induce platelet MRP4 over-expression throu-
gh the activation of the nuclear receptor PPARa 
in megakaryocytes18,19. In this work we report for 
the first time that aspirin and other non-aspirin 
NSAIDs induce an enhancement of MRP4 expres-
sion in a human ectopic endometrial epithelial cell 
line (12Z cells). In addition we demonstrate that the 
nuclear receptor involved is PPARa. In fact, MRP4 
and PPARa mRNA expression are enhanced in 
12Z cells treated with aspirin. The involvement 
of PPARa in MRP4 up-regulation was confirmed 
by the fact that 12Z cells transfected with PPARa 
specific siRNA didn’t show a significant increase 
of aspirin dependent on both PPARa and MRP4 
mRNA up-regulation; while cells transfected with 
control non specific siRNA (CTR-si) show the same 
aspirin-induced MRP4 up-regulation. Arachidonic 
acid is metabolized through three different enzy-
matic pathways: cyclooxygenase, lipoxygenase and 
cytochrome P450 dependent. Both lipoxygenase 
and cytochrome P450 enzymes are insensitive to 
aspirin and non-aspirin NSAIDs action and they 
produce leukotriene B4 and 20-HETE metabolites 
Figure 4. Scalar doses of Aspirin and NSAIDs stimulate endogenous MRP4 and PPARα mRNA expression in 12Z cells. 
(A-C) Q-RT-PCR analysis of endogenous MRP4 expression in 12Z cells treated with different doses of aspirin (A), diclofenac 
(B) and nimesulide (C) (25 μM, 50 μM and 100 μM for 48 h) compared to control culture (Ctr); data were normalized with 
ACTB expression and reported as mean ±SD of 2 experiments (*p<0.05, **p<0.01, ***p<0.0001, NS: Not Significant; t-test). 
(D-F) Q-RT-PCR analysis of endogenous PPARa expression in 12Z cells treated with different doses of aspirin (D), diclofe-
nac (E) and nimesulide (F) (25 μM, 50 μM and 100 μM for 48h) compared to control culture (Ctr); data were normalized with 
ACTB expression and reported as mean ±SD of 2 experiments; (*p<0.05, **p<0.01, ***p<0.0001, NS: Not Significant; t-test).
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respectively, whose production is higher in aspiri-
nated cells27,28. These arachidonic acid metabolites, 
LTB429 and 20-HETE30 are PPARa ligands. Thus 
we can hypothesize that, in 12Z cells, when COX-
1 is inhibited PPARa is activated by lipoxygena-
se and cytochrome P 450 metabolites, leading to 
MRP4 up-regulation. This hypothesis is supported 
by the fact that in 12Z cells other anti-inflamma-
tory inhibitors of COX-1 and COX-2 (diclofenac, 
nimesulide, acetaminophen and ketoprofen) caused 
increased MRP4 expression in comparison with 
untreated cells. In the same conditions the expres-
sion of the nuclear receptor PPARa is enhanced 
in treated cells compared to untreated cells. The 
involvement of PPARa in MRP4 up-regulation is 
confirmed in PPARa specific siRNA transfected 
12Z cells. PPAR-si treated cells didn’t show any 
significant increase in PPARa and MRP4 mRNA 
expression after diclofenac treatment; while cel-
ls transfected with control non specific siRNA 
(CTR-si) exhibited the same diclofenac-induced 
expression changes as untransfected cells. Among 
the anti COX-1 and COX-2 drugs analyzed, na-
proxen and ibuprofen did not increase MRP4 and 
PPARa expression in human ectopic endometrial 
epithelial cells, probably due to the fact that these 
drugs do not inhibit COX enzymes in an efficient 
manner31. Thus, we can affirm that in vitro treat-
ment with aspirin and non-aspirin NSAIDs, except 
for naproxen and ibuprofen, caused a statistically 
significant increase of MRP4 expression and this 
modulation is PPARa dependent. With our results 
we can hypothesize that, in 12Z cells, when COX-1 
and/or COX-2 are inhibited PPARa is activated by 
lipoxygenase and cytochrome P 450 metabolites, 
resulting in MRP4 up-regulation. It was previously 
suggested that MRP4 overexpression in ectopic tis-
Figure 5. Aspirin and NSAIDs increase MRP4 via 
a PPARα dependent mechanism in 12Z cells. Control 
non-specific siRNA (CTR-si) and PPARa specific siRNA 
(PPAR-si) transfected 12Z cells were treated with either 
aspirin or diclofenac (50 μM for 48 h). (A) Q-RT-PCR analy-
sis of endogenous PPARa expression; data were normalized 
with ACTB expression and reported as mean ±SD of 3 expe-
riments (*p<0.05, NS: Not Significant; t-test). (B) Q-RT-
PCR analysis of endogenous MRP4 expression; data were 
normalized with ACTB expression and reported as mean 
±SD of 3 experiments (*p<0.05, NS: Not Significant; t-test).
Figure 6. NSAIDs induce PGE2 release by endometrio-
tic epithelial cells. Prostaglandin (PG) E2 and its tran-
sporter multidrug resistance-associated protein 4 (MRP4) 
are upregulated in NSAID-treated cells in comparison to 
control cells. After treatment, supernatants were collected 
and PGE2 content quantified using an EIA kit according to 
the manufacturer’s instructions. PGE2 levels (pg/10
5 cells) 
are reported as a ratio between treated and untreated cells 
(CTR: 3.7±1.1 pg/105 cells). Data represent the mean ± SD 
from 4 independent experiments (*p<0.05, **p<0.01; t-test).
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sue plays a pivotal role in endometriosis, because it 
facilitates PGE2 secretion
13, as it was transported 
with high affinity by MRP432. Prostaglandin E2 is 
a pro-inflammatory lipid mediator derived from 
arachidonic acid metabolism which plays a pivotal 
role in endometriosis-associated inflammation and 
pain33, and its production is augmented in lesions 
and in the peritoneal cavity34,35. NSAIDs are often 
the first-line treatment for endometriosis36. As the 
NSAID dependent MRP4 over-expression persi-
sts for a longer period than its capability to redu-
ce COX-1 and/or COX-2 activity, we can suggest 
that after a high dose of NSAIDs there is a period 
in which the ratio between MRP4 expression and 
PGs production is unbalanced, leading to augmen-
ted PGs levels in peritoneal fluid and consequently 
increasing the risk of developing endometriosis. 
Lipoxin A4 may reduce MRP4 over-expression by 
reducing PPAR-activation, and our results further 
support its capability to inhibit endometriosis pro-
gression in a mouse model37. Our suggestion was 
corroborated by the fact that 24 hours after drug 
removal from the medium, when MRP4 levels are 
still high, NSAIDs do not affect COX-1 and COX-
2 activity and PGE2 secretion is enhanced. These 
results indicate that the NSAID-induced MRP4 
over-expression leads to enhancement of PGE2 
secretion. These PGE2 increase may be important 
to promote endometriosis progression by affecting 
cell proliferation, angiogenesis and the immune re-
sponse. 
Conclusions
Many women use NSAIDs; treatment with 
NSAIDs was investigated because they are bene-
ficial in women with primary dysmenorrhea and 
are relatively safe36, but we showed that these drugs 
modify gene expression in endometrial cells. Our 
data further support the consideration of PPARa 
or MRP4 as potential targets for endometriosis the-
rapy.
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